Molecular Pharming Market Size, Share, By Crop Source, Technology, Application, End-User, and Region - Trends, Analysis, and Forecast till 2035

Molecular Pharming Market Size, Share, By Crop Source, Technology, Application, End-User, and Region - Trends, Analysis, and Forecast till 2035

Molecular pharming is the process of using transgenic plants to generate recombinant proteins, where the proteins that have been genetically modified to improve their characteristics or to create completely new proteins that are not found in the plant naturally. Focused on the utilization of genetically modified plants, the target market growth represents a revolutionary sector of the biotechnology and pharmaceutical industry.

Molecular Pharming Market Report Highlights:

By 2035, the market is expected to grow to a valuation of about USD 4.8 billion.

In 2024, molecular pharming market size was valued at USD 2.4 billion.

The target market is growing at CAGR 7.9%.

Asia Pacific is anticipated to develop at the quickest rate during the forecast period.

North America is accounted for the biggest market share in 2024.

By crop source, the maize segment is estimated to account for the largest share of the market.

Based on technology, the market is being dominated by the agroinfiltration segment.

On the basis of application, the recombinant antibodies segment is expected to lead the market during the forecast period.

The pharmaceutical and biotechnology companies end-user segment is expected to lead the market during the forecast period.

Molecular Pharming Market Key Highlights:

In May 2024, Scientists are planting a CRISPR/Cas9-modified rice variety in test fields across India after a recent relaxation of regulations on gene-edited crops. The shift allows field trials of crops developed through gene-editing processes SDN1 and SDN2, which alter plant traits by making edits in the gene without adding any new genetic material. An Institutional Biosafety Committee (IBSC) will oversee the progress of the crops and will certify that gene-edited crops are free of foreign DNA before their commercial release.

Key Benefits of Purchasing This Report

Gain valuable insights into revenue projections for the overall market and its sub-segments, benefiting industry leaders and new entrants.

Enhance your understanding of the competitive landscape to refine business positioning and optimize go-to-market strategies.

Stay informed on the latest trends in the Molecular Pharming Market, including key drivers, challenges, opportunities, and barriers.

Molecular Pharming Market Report Analysis:

Regulatory Compliance and Clinical Trials:

The progression of molecular pharming products into human clinical trials is an important priority for the field. It demonstrates that the technology is moving beyond basic scientific proof of concept studies and towards clinical development of products.

For most products this represents the first time that the manufacturing process will have come under any form of scrutiny from regulatory assessors. In the U.K., all clinical trials are conducted according to ICH GCP guidelines, specifically in accordance with the ethical principles in the Declaration of Helsinki, the regulatory requirements of the U.K. National Medicines Regulatory Agency (MHRA), the Association of British Pharmaceutical Industry (ABPI) guidelines and the U.K. Department of Health “Research Governance Implementation Plan”.

Segmentation:

By Crop Source:

Rice

Alfalfa

Barley

Maize

Others

By Technology:

Gene Gun

Electroporation

Agroinfiltration

Other Technologies

By Application:

Recombinant Antibodies

Hormones

Vaccines

Industrial Enzymes

Technical Reagents

Other Applications

By End User:

Hospitals and Clinics

Pharmaceutical and Biotechnology Companies

Academic and Research Institutions

Contract Manufacturing Organizations (CMOs)

Agricultural Producers

By Region:

North America

U.S.

Canada

Europe

Germany

U.K.

France

Russia

Italy

Spain

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

Australia

Indonesia

Malaysia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Rest of Latin America

Middle East & Africa

GCC

Israel

South Africa

Rest of Middle East & Africa

Molecular Pharming Market Competitive Landscape:

Moolec Science SA

Mozza

Protalix Biotherapeutics, Inc.

ORF Genetics

Bright Biotech

Nobell Foods

Planet Biotechnology Inc.

Agrenvec S.L.

Leaf Systems International Limited

Baiya Phytopharm

Cape Bio Pharms

Transactiva Srl

BioBetter

Miruku

Tiamat Science

Key Questions Answered in This Report

1. What was the size of the Molecular Pharming Market in 2024?

2. What is the expected growth rate of the Molecular Pharming Market during 2025-2035?

3. What are the key factors driving the Molecular Pharming Market?

4. What is the breakup of the Molecular Pharming Market based on the distribution channel?

5. What are the key regions in the Molecular Pharming Market?

6. Who are the key players/companies in the Molecular Pharming Market?

7. What are the drivers, restraints, and opportunities in the Molecular Pharming Market?